Director Segal reports holdings in Aktis Oncology (AKTS) Form 3 filing
Rhea-AI Filing Summary
Aktis Oncology director Lloyd Mitchell Segal filed an initial Form 3 reporting his equity interests as of January 8, 2026. Indirect holdings include 13,142 shares of Series A Redeemable Convertible Preferred Stock and 6,489 shares of Series B Redeemable Convertible Preferred Stock held by Arvala, Inc., where he is president and sole stockholder and may share voting and dispositive power. Each preferred share is convertible into common stock on a 3.8044-for-1 basis and will automatically convert to common stock immediately before the closing of Aktis Oncology’s initial public offering. He also reports several stock options for common stock, including grants covering 32,856, 31,542, 6,571, 10,514 and 18,933 shares at exercise prices ranging from $1.45 to $18.00, with one grant fully vested and others vesting monthly or in full on January 8, 2027 subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Segal Lloyd Mitchell
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series A Redeemable Convertible Preferred Stock | -- | -- | -- |
| holding | Series B Redeemable Convertible Preferred Stock | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings After Transaction:
Series A Redeemable Convertible Preferred Stock — 13,142 shares (Indirect, See Footnote);
Series B Redeemable Convertible Preferred Stock — 6,489 shares (Indirect, See Footnote);
Stock Option (Right to Buy) — 100,416 shares (Direct)
Footnotes (8)
- F1. Each share of Series A Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis and have no expiration date. All shares of Series A Redeemable Convertible Preferred Stock will automatically convert on a 3.8044-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
- F2. Each share of Series B Redeemable Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 3.8044-for-1 basis and have no expiration date. All shares of Series B Redeemable Convertible Preferred Stock will automatically convert on a 3.8044-for-1 basis into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock.
- F3. Consists of 13,142 shares of Series A Redeemable Convertible Preferred Stock and 6,489 shares of Series B Redeemable Convertible Preferred Stock held by Arvala, Inc.(f/k/a 3996953 Canada Inc.). The Reporting Person is the president and sole stockholder of Arvala, Inc. and may be deemed to share the voting and dispositive power over the shares held by Arvala, Inc.
- F4. These options have vested in full.
- F5. 25% of the original number of shares subject to the option vested on November 1, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
- F6. Beginning on January 1, 2024, 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments, subject to the Reporting Person's continuous service through each vesting date, inclusive.
- F7. Beginning on October 9, 2024, 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments, subject to the Reporting Person's continuous service through each vesting date, inclusive.
- F8. The number of shares subject to the option shall vest in full on January 8, 2027, subject to the Reporting Person's continuous service through such vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the AKTS Form 3 filed by Lloyd Mitchell Segal show?
The Form 3 reports Lloyd Mitchell Segal’s status as a director of Aktis Oncology, Inc. and discloses his indirect preferred share holdings via Arvala, Inc. along with several stock option awards for common stock.
What stock options for Aktis Oncology common stock does Lloyd Mitchell Segal report?
Segal reports multiple stock options (rights to buy) for Aktis Oncology common stock, including grants for 32,856, 31,542, 6,571, 10,514, and 18,933 shares with exercise prices of $1.45, $3.66, $4.95, $10.66, and $18.00, respectively.
What are the key vesting terms of Lloyd Mitchell Segal’s AKTS stock options?
One option grant has vested in full. Another vested 25% on November 1, 2023 with the remainder vesting in equal monthly installments. Additional grants vest in monthly installments beginning January 1, 2024 and October 9, 2024, and one grant vests in full on January 8, 2027, all subject to Segal’s continuous service.
Is the Aktis Oncology Form 3 a new transaction or a holdings report?
This Form 3 is an initial statement of beneficial ownership, listing Lloyd Mitchell Segal’s existing indirect preferred share holdings via Arvala, Inc. and his stock options, rather than reporting new purchase or sale transactions.